trending Market Intelligence /marketintelligence/en/news-insights/trending/mm7czH-kDc45D8XUnXATBg2 content esgSubNav
In This List

Ionis CEO to become executive chairman in 2020

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Ionis CEO to become executive chairman in 2020

Ionis Pharmaceuticals Inc. said founder and CEO Stanley Crooke will transition to executive chairman of the company's board of directors, effective January 2020.

Brett Monia, who has been COO for the previous year and a founding member of Carlsbad, Calif.-based Ionis, will take over from Crooke as CEO.

Crooke will continue to be in charge of board affairs and will provide strategic advice, as well as participate in the scientific activities of the company.

Ionis develops RNA-targeted therapies for genetic diseases such as spinal muscular atrophy, transthyretin amyloidosis and familial chylomicronemia syndrome.